Mona Ridderheim - Concepedia

Author

Mona Ridderheim

Lund University

Also Known As

M RIDDERHEIM, M Ridderheim, M. RIDDERHEIM, M. Ridderheim, MONA RIDDERHEIM, Mona Ridderheim, TOMAS OHLSSON

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Lund University Umeå University KU Leuven University of Split Norwegian Cancer Society

About

Mona Ridderheim is an author at Lund University specializing in medicine, obstetrics, and ovarian cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	579
2	Obstetrics	7	7	506
3	Pathology	4	4	450
4	Public Health	1	1	13
5	Endocrinology	1	1	13

Mona Ridderheim

Publications

883

Citations

H-Index

Page 1

	Year	Citations
Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Rudi Henriksen, Keiko Funa, Erik Wilander, PubMed ThrombopoiesisMalignant DiseasePlatelet-derived Growth FactorMedicineBlood Platelet	1993	219
Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum Per Rosenberg, Ha ̊kan Andersson, Karin Boman, Acta Oncologica	2002	140
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer Susanne Malander, Eva Rambech, Ulf Kristoffersson, Gynecologic Oncology MedicineColorectal CancerGynecologyPathologyCancer Genetics	2005	125
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations Susanne Malander, Mona Ridderheim, Anna Måsbäck, European Journal of Cancer Somatic VariantMedicineGerm Line Brca1Brca2 MutationsPathology	2003	91
Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: A pilot study of a new digitized scalp-cooling system used in 74 patients Mona Ridderheim, Maria Bjurberg, Anita Gustavsson Supportive Care in Cancer Scalp-cooling SystemHyperthermiaThermal TherapyScalp HypothermiaDermatology	2003	73
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin Gunnar B. Kristensen, Ignace Vergote, Gavin Stuart, International Journal of Gynecological Cancer	2003	52
A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer Agnieszka Jagiełło-Gruszfeld, Sergei Tjulandin, Natalya Dobrovolskaya, Oncology	2010	36
Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors Peter Lindgren, T. Bäckström, Carl-Gustav Mahlck, International Journal of Oncology	2001	35
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG Kristina Lindemann, René dePont Christensen, I. Vergote, Annals of Oncology Eortc GcgMedicineCancer ManagementGynecologyFirst-line Treatment	2012	33
FDG‐PET in cervical cancer: staging, re‐staging and follow‐up Maria Bjurberg, Elisabeth Kjellén, Tomas Ohlsson, Acta Obstetricia Et Gynecologica Scandinavica	2007	18

Page 1